Ethics roundtable: Using new, expensive drugs
- PMID: 12493067
- PMCID: PMC153428
- DOI: 10.1186/cc1533
Ethics roundtable: Using new, expensive drugs
Abstract
Costly genetically engineered therapies, which threaten to cripple the health care industry economy and undermine the common good if applied indiscriminately, loom on the horizon. The spectrum of applicable candidates include moribund nursing home patients at the end of life. They will be fair game for therapy that will ultimately send them back to nursing homes to return later with the same condition. 'Quality of life' assessments that limit patient autonomy may be forced as a result. Discussants from South Africa, New Zealand, and the USA suggest methods to deal with this issue in a just and ethical framework.
Similar articles
-
Conceptions of family-centered medical decision making and their difficulties.Camb Q Healthc Ethics. 2003 Spring;12(2):196-200. doi: 10.1017/s0963180103002111. Camb Q Healthc Ethics. 2003. PMID: 12764886 No abstract available.
-
Priority-setting ethics in public health.J Public Health Policy. 2002;23(4):399-412. J Public Health Policy. 2002. PMID: 12532681
-
Quality-adjusted life-years. Ethical implications for physicians and policymakers.JAMA. 1990 Jun 6;263(21):2917-21. doi: 10.1001/jama.263.21.2917. JAMA. 1990. PMID: 2110986
-
Clinical decision-making in catastrophic situations: the relevance of age. Report of a conference convened by the American Geriatrics Society, April 17-18, 1987.J Am Geriatr Soc. 1988 Oct;36(10):919-37. doi: 10.1111/j.1532-5415.1988.tb05786.x. J Am Geriatr Soc. 1988. PMID: 3049750 Review. No abstract available.
-
Therapeutic drug use in Bangladesh: policy versus practice.Indian J Med Ethics. 2008 Jan-Mar;5(1):24-5. doi: 10.20529/IJME.2008.009. Indian J Med Ethics. 2008. PMID: 18630250 Review.
References
-
- Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Jr, for the Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. - PubMed
-
- Seltzer JL, Wordell CJ, Nash D, Johnson NE, Gottlieb JE. P & T Committee response to evolving technologies: preparing for the launch of high-tech, high-cost products. Roundtable discussion. Hosp Formul. 1992;27:379–380. - PubMed
-
- Anonymous Understanding costs and cost effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. Am J Respir Crit Care Med. pp. 540–550. - PubMed
-
- Hardin G. The tragedy of the commons. The population problem has no technical solution; it requires a fundamental extension in morality. Science. 1968;162:1243–1248. - PubMed
-
- McIntyre RC, Jr, Pulido EJ, Bensard DD, Shames BD, Abraham E. Thirty years of clinical trials in acute respiratory distress syndrome. Crit Care Med. 2000;28:3314–3331. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical